Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.415 USD | -4.34% | -7.08% | +105.42% |
07/05 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
06/05 | Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+105.42% | 344M | |
+9.53% | 115B | |
+9.59% | 105B | |
-12.69% | 22.71B | |
+2.94% | 21.83B | |
-10.42% | 18.18B | |
-41.92% | 16.52B | |
-16.11% | 16.01B | |
+1.21% | 14.14B | |
+18.08% | 10.71B |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics' Joint Venture Doses First Patient in Phase 3 Trial of Lymphoma Drug Candidate Zynlonta